Search

Displaying results 2811 - 2820 of 10000 in total
  1. Drug

    Marstacimab

    go.drugbank.com/drugs/DB17725
    ApprovedInvestigational

    [A264608] Marstacimab is used to prevent bleeding episodes in patients with hemophilia,[L51803] which is an X‐linked bleeding disorder characterized by coagulation clotting factor deficiency. … [L51803] It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anticoagulant.

  2. Drug

    Reynoutria multiflora root

    go.drugbank.com/drugs/DB14295
    Investigational

    Reynoutria multiflora root is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Synonyms: Fo Ti Root
  3. Drug

    Gadopiclenol

    go.drugbank.com/drugs/DB17084
    ApprovedInvestigational

    It is indicated for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and the body. … [A254002] Gadopiclenol has high kinetic stability and a high r1 relaxivity, allowing it to be used at lower doses than classic extracellular GBCAs.

  4. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    [L2336] Opicapone is used for adjunct therapy to levodopa and carbidopa in adult patients with Parkinson's disease and end-of-dose motor fluctuations. … Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.

  5. Drug

    Colfosceril palmitate

    go.drugbank.com/drugs/DB09114
    ApprovedWithdrawn

    [A31510] It was part of the first generation of commercially available artificial surfactants.[T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990. … Colfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome.

  6. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer. … [L64113] It is the first hepcidin mimetic approved for polycythemia vera.[L64113]

  7. Drug

    Bazedoxifene

    go.drugbank.com/drugs/DB06401
    ApprovedInvestigational

    In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. … In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as

  8. Drug

    CX-046684

    go.drugbank.com/drugs/DB19414
    Approved

    CX-046684 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage KP.2. … It is the active ingredient of the 2024-2025 formulation of Moderna's Spikevax vaccine.[L40074]

  9. Drug

    gamma-Hydroxybutyric acid

    go.drugbank.com/drugs/DB01440
    ApprovedIllicitInvestigational

    It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985). … It is used illegally under the street names Juice, Liquid Ecstasy or simply G, either as an intoxicant, or as a date rape drug.

    Synonyms: oxy-n-butyric acid
  10. Drug

    Eflapegrastim

    go.drugbank.com/drugs/DB15001
    ApprovedInvestigational

    [L43135] Eflapegrastim is a form of recombinant human G-CSF comprising a human G-CSF analog coupled to the Fc fragment of human IgG4 via a polyethylene glycol linker. … The primary factor associated with FN risk is the chemotherapy regimen being administered - regimens are classified as either high-, intermediate-, or low-risk for FN, and relevant guidelines recommend